Analytical Data
-
基因名
GABRP
- Application
-
别名
GABA(A) receptor subunit pi
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O00591
-
表达区间
17-242aa
-
分子量
28.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GABRP (Gamma-Aminobutyric Acid Receptor Pi) is a subunit of the GABA (gamma-aminobutyric acid) receptor, which plays a crucial role in inhibitory neurotransmission in the central nervous system. As an important member of the GABA receptor family, GABRP is involved in various physiological processes, including modulation of anxiety, memory formation, and muscle relaxation. Research into GABRP has gained momentum due to its potential implications in neuropsychiatric disorders such as anxiety disorders, depression, and epilepsy, where GABAergic signaling may be disrupted. The study of GABRP's structure and function, particularly through the development of recombinant protein forms, allows researchers to elucidate its role within the GABA receptor complex and investigate its pharmacological properties. Advances in recombinant protein technology enable the efficient production of GABRP, facilitating high-resolution structural studies and functional assays. These investigations can ultimately lead to the identification of new therapeutic targets and strategies for treating conditions associated with GABAergic dysfunction. Consequently, GABRP stands out as a promising subject of research within neuropharmacology, with the potential to contribute to novel treatment approaches for various mental health disorders.
